A comparative effectiveness study of glucose-lowering drugs finds the GLP-1 receptor agonists most protective against cardiovascular events, followed by SGLT2i and two older drug classes.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/among-t2d-drugs-glp-1s-top-others-reducing-cv-events-2025a1000sqi?src=rss
Author :
Publish date : 2025-10-22 12:50:00
Copyright for syndicated content belongs to the linked Source.